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INTRA-ARTICULAR DELIVERY OF ENCAPSULATED HUMAN 
MESENCHYMAL STEM CELLS REDUCES OSTEOARTHRITIS 
PROGRESSION IN A RAT MODEL 
JAY MICHAEL MCKINNEY JR. 
ABSTRACT 
Osteoarthritis (OA) is a degenerative disease of the joint that leads to joint 
instability, degradation of the articular cartilage surface and eventually joint failure. 
Articular cartilage surfaces exhibit unique mechanical behaviors, bearing and distributing 
loads across joint surfaces, but have poor regenerative capacities. Human Mesenchymal 
Stem Cells (hMSCs) present a promising treatment to target OA, relying on their 
regenerative capacity and structural contributions to tissue repair, along with their 
immunomodulatory and anti-inflammatory properties. The multipotency of hMSCs allow 
these cells to differentiate towards osteogenic, chondrogenic and adipogenic lineages and 
directly incorporate into native tissue. hMSCs also possess the capacity to induce 
numerous paracrine-mediated processes including the recruitment of stem and progenitor 
cells, prevention of apoptosis, facilitation of beneficial remodeling and modulation of the 
immune response. Through encapsulating hMSCs, the effects of their paracrine action 
were studied directly, as the capsule presents a mechanical barrier for direct physical 
interaction and integration of these cells within the native tissue. The objective of this 
study was to utilize encapsulation of hMSCs to determine the paracrine effects of hMSCs 
on the progression of OA. OA was surgically induced in rats via the medial meniscus 
transection (MMT) surgery, which presents the phenotypical cartilage degradation 
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associated with OA at 3 weeks. The efficacy of hMSC intervention was assessed using 
Lewis Rats with MMT (n=5 per group). Intra-articular injections of encapsulated hMSCs 
were given one day post-op and 3 weeks post-op for the 3-week and 6-week MMT 
studies, respectively. Animals were euthanized on the final day for both the immediate 
and delayed treatment studies. Micro-structural changes of the articular cartilage, 
osteophytes and subchondral bone of the medial tibial plateau were assessed using 
contrast enhanced microCT. We hypothesized that the intra-articular delivery of 
encapsulated hMSCs will have a positive effect, via paracrine-mediated action, on the 
onset and development of OA. The capsules also have the potential to improve retention 
and cell viability in the knee joint space. Each of these factors could contribute to 
enhanced therapeutic potential of the hMSC treatment. Utilizing NIR labeled sodium 
alginate capsules, a retention profile for the capsules yielded a tau value of 11.48 days, 
whereas previous studies have shown scaffold free hMSCs show complete clearance in 7 
days. The 3-week MMT, run to analyze the effects of immediate treatment of 
encapsulated hMSCs on the onset of OA, showed a trend towards decreased cartilage 
thickness and a decreased surface roughness for the hMSC group in comparison to the 
Saline group, specifically. Additionally, the hMSC group showed a trend towards 
increased mineralized osteophyte volume for the hMSC group in comparison to the 
Saline group. Analysis of the subchondral bone yielded no differences between the 
hMSC and Saline groups for bone morphology. The 6 week MMT study was run to 
analyze the effects of a delayed treatment of encapsulated hMSCs on OA after the disease 
had developed. This study showed a similar result with the immediate treatment study for 
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surface roughness, with the hMSC group showing a decrease in comparison to the Saline 
group. However, no differences were noted for cartilage thickness between the two 
respective groups. To further analyze the cartilage in the later stages of OA, exposed 
bone was quantified yielding a trend towards decreased exposed bone in the hMSC group 
in comparison to the Saline group. The mineralized osteophyte volume for the hMSC 
group, of the delayed treatment study, yielded a significantly higher value than all other 
groups. Additionally, the subchondral bone of the hMSC group trended towards a 
decreased porosity in comparison to the Saline group. This is one of the first studies to 
use sodium alginate encapsulation of hMSCs as an innovative scaffold means for intra-
articular injections into the knee space. Encapsulated hMSCs permitted not only 
enhanced cellular retention in the knee space but showed a potential chondroprotective 
role of the paracrine signaling properties of hMSCs in the early stages of OA. These 
advantages of encapsulated hMSCs were countered by enhancements of secondary OA 
phenotypic changes, mainly increased mineralized osteophyte volume and a trend 
towards increased subchondral bone sclerosis in the later stages of OA. hMSCs have 
shown great potential as disease modifying drugs and through this study we have further 
explored the efficacy of these drugs for future treatments of OA. This study has high 
clinical relevance and with clinical practice running well ahead of current scientific 
evidence, it is imperative that these findings be considered not only in pre-clinical work 
but in current and future clinical trials.   
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INTRODUCTION 
Osteoarthritis (OA) is the most common form of arthritis, currently affecting over 
30.8 million people in the United States (US) (Cisternas, Murphy et al. 2016). OA is 
associated with the breakdown of the cartilaginous surfaces of the articulating joints in 
the body. Recent incidence reports cite estimates that OA will affect over 67 million 
people in the US by 2020 and disease prevalence is only expected to increase with the 
continued aging of the American population (Bijlsma, Berenbaum et al. 2011, Zhang and 
Jordan 2010). Although aging is a significant risk factor, OA is a multifactorial condition 
with numerous factors contributing to its pathogenesis (Bijlsma, Berenbaum et al. 2011). 
Family history, gender, metabolism and history of prior joint injury are all factors that 
determine an individual’s risk for OA (Bijlsma, Berenbaum et al. 2011). The financial 
burden of OA is significant, with annual medical expenditures totaling approximately 
$186 billion annually (Kotlarz, Gunnarsson et al. 2009). These costs of care are only 
expected to increase in the near future in parallel with the aging US population (Bitton 
2009). Currently, all available treatments for OA, such as analgesics, weight loss and 
physical therapy, are limited to providing symptomatic relief (Arden and Leyland 2013). 
There is a notable need for the development of disease modifying drugs. A 
comprehensive understanding of the pathophysiology of OA is essential for the 
development of therapies to delay progression of OA in individuals with this disease.   
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Osteoarthritis 
OA is a degenerative disease of the joints that leads to joint instability, 
degradation of the articular cartilage surfaces and eventually joint failure. While any joint 
can be affected by OA, the knee is the most common site of development (Martel-
Pelletier, Wildi et al. 2012). Other frequently involved joints include the hip and joints of 
the hands and feet (Martel-Pelletier, Wildi et al. 2012). Articular cartilage is a smooth 
tissue that covers the articulating surfaces on the ends of bones throughout the body, 
allowing them to glide over one another smoothly with minimal friction (Forster and 
Fisher 1996). These cartilage surfaces are made up of chondrocytes and an extensive 
extra cellular matrix (ECM), composed mainly of proteoglycans (PG) and collagen 
(Huber, Trattnig et al. 2000). Cartilage exhibits unique mechanical behaviors, bearing 
and distributing loads across joint surfaces (Huber, Trattnig et al. 2000). Due to its load 
bearing functionality, articular cartilage is highly susceptible to damage during high 
impact activity and is susceptible to wear and tear over time. These cartilaginous surfaces 
present a poor capacity for regeneration, with two of the major factors leading to this 
potentially being that these tissues are largely avascular and contain minimal innervation 
(Huber, Trattnig et al. 2000). Articular cartilage degeneration is a staple of OA in which 
the breakdown of the cartilaginous surfaces leads to matrix fibrillation, fissure 
appearance, macroscopic ulceration and eventually full-thickness loss of the articular 
cartilage surfaces, resulting in bone on bone contact (Martel-Pelletier 2004). Temporal 
destruction of the articular cartilage surfaces stimulates synovial cells and chondrocytes 
to secrete proteolytic enzymes and other catabolic factors, such as matrix 
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metalloproteinase (MMP), nitric oxide (NO) and prostaglandins, which result in further 
degradation of the articular cartilage surfaces (Stone, Loeser et al. 2014).  
 
Figure 1. Illustration dEPICting the associated pathological changes that occur in the OA 
pathology. All pathological changes noted in the OA panel on the right side of the 
diagram are analyzed, directly or indirectly, in this study with exception to meniscal 
physiology and the inflammation of the synovial membrane (Zhang, Ouyang et al. 2016). 
 
The integrity of articular cartilage relies on subchondral bone for mechanical 
support and the supply of nutrients (Wen, Lu et al. 2014). Subchondral bone undergoes 
constant adaptation in response to changes in the biomechanical environment of the joint 
space as the articular cartilage – subchondral bone interface is remodeled in early OA, 
leading to an upregulation in the formation of new bone (Madry, Dijk et al. 2010). This 
enhanced proliferation leads to both thickening of the subchondral bone as well as the 
formation of osteophytes, characterized as bony outgrowths that form on the margins of 
joints (Madry, Dijk et al. 2010).  Other major radiological features that result due to the 
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disturbance of the articular cartilage – subchondral bone interface include bone sclerosis, 
or hardening of the bone and the development of bone cysts (Figure 1) (Wen, Lu et al. 
2014).   
Although OA is generally associated with degeneration of the cartilaginous 
surfaces, recent studies suggest that low-level inflammatory responses can promote 
symptomatic development and accelerate disease progression (Liu-Bryan and Terkeltaub 
2015). Even though the interplay between cartilage and the immune system is not well 
understood, it has been found that some of the catabolic products of cartilage 
degeneration might activate macrophages and other immune cells to release inflammatory 
cytokines, further potentiating the progression of damage to the chondrocytes (van Lent, 
Grevers et al. 2008). Pathological changes may also persist in the supporting structures of 
the articulating joints including the synovial membrane, tendons and ligaments (Bijlsma, 
Berenbaum et al. 2011).   
Despite the major burden of this condition, due to its chronicity and complexity, 
there are no current effective disease modifying drugs available and existing symptomatic 
treatment options are limited (Chu, Williams et al. 2012). Mesenchymal Stem Cells 
(MSC) present a promising treatment to target OA, relying on their regenerative capacity 
and structural contributions to tissue repair, along with their immunomodulatory and anti-
inflammatory properties.   
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Mesenchymal Stem Cells  
MSCs have been implicated in the cellular mechanisms responsible for normal 
cellular turnover and maintenance of adult mesenchymal tissues, due to their 
multipotency and secretome of cytokines and growth factors (Pittenger, Mackay et al. 
1999). Interest in MSC therapeutics for cartilage regeneration in OA has been frequently 
discussed in the literature (Djouad, Bouffi et al. 2009, Mazor, Lespessailles et al. 2014). 
MSCs are highly appealing for the development of novel therapeutics as they are easy to 
isolate from adult tissues, including bone marrow, synovium and adipose tissue and can 
be cultured and expanded in vitro with relative ease (Mosna, Sensebé et al. 2010). MSCs 
are characterized by their ability to adhere to plastic, to express CD105, CD73 and CD90 
cell surface markers and to differentiate towards osteogenic, chondrogenic and 
adipogenic lineages (Dominici, Le Blanc et al. 2006).  
The definitive mechanisms behind MSC based therapies are still unclear but 
several mechanisms have been postulated. In certain degenerative diseases, including 
OA, the stem cell population in target environments is depleted resulting in native tissue 
with less ability to proliferate and differentiate (Murphy, Dixon et al. 2002). Therefore, 
the direct delivery of MSCs presents a promising means for treatment (Murphy, Dixon et 
al. 2002). The ability of these cells to differentiate into various cell lineages presents 
great regenerative promise, although it has been postulated that the benefits depend, in 
part, on mechanisms involving paracrine cellular communications (Caplan 2009).  
Stem cells release a broad range of cytokines and growth factors, which allow for 
paracrine communication with cells in the local environment (Skalnikova, Motlik et al. 
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2011). Paracrine-mediated processes involving bone marrow derived MSCs include the 
recruitment of stem and progenitor cells, prevention of apoptosis, facilitation of 
beneficial remodeling and modulation of the immune response (Caplan and Dennis 
2006). Among the many growth factors released by MSCs, transforming growth factor 
(TGF) β, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(VEGF) stimulate proliferation and angiogenesis in various cell types environment 
(Skalnikova, Motlik et al. 2011). Other factors, such as insulin-like growth factor (IGF) 1 
and interleukin (IL) 6, possess the capacity to rescue cells from apoptosis induced by 
trauma and oxidative environments (Rehman, Traktuev et al. 2004). Furthermore, MSCs 
have been shown to possess anti-fibrotic mechanisms (Maria, Bony et al. 2015). When 
tissues undergo repeated damage, the tissue undergoes remodeling and fibrosis, which 
involves excessive buildup of ECM, resulting in the formation of scar tissue at the site of 
injury (Gurtner, Werner et al. 2008). Scar tissue formation results in the production of a 
non-functioning fibrotic mass that further limits the functionality of the injured tissue 
(Gurtner, Werner et al. 2008). Through their regulation of ECM remodeling components, 
such as hepatocyte growth factor (HGF) and adrenomedullin (ADM), MSCs can regulate 
scar tissue formation (Djouad, Bouffi et al. 2009).  In addition to their potential protective 
roles, MSCs demonstrate a potent ability to modulate the immune response, with anti-
proliferative and anti-inflammatory capacity.  
The mechanisms of MSC immunological effects are only partially known, but the 
induction of MSC-mediated immunosuppression has been shown to be largely mediated 
through soluble mechanisms (Djouad, Bouffi et al. 2009). Secretion of NO by MSCs, 
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after being activated by the proinflammatory cytokine interferon (IFN) γ, has been shown 
to inhibit the proliferation of T lymphocytes (Ren, Zhang et al. 2008, Sato, Ozaki et al. 
2007). Prostaglandin E2 secretion by MSCs, following activation by Tumor Necrosis 
Factor (TNF) and IFN-γ, may also play a role in immunosuppression in its action as a 
powerful immune suppressant that inhibits T-cell mitogenesis and IL-2 production, 
whose primary function is the promotion of T regulatory cells (Aggarwal and Pittenger 
2005, Malek 2003). The therapeutic efficacy of the paracrine mechanisms of MSCs, on 
OA, will be the focus of this study.  
Cellular Encapsulation 
Tissue engineering approaches involving the use of MSCs have been used for 
various applications to effectively deliver stem cells to target areas of injury. In tissue 
engineering it is important to not only fabricate replacement tissues that share 
morphologic and molecular similarities with the native tissue but also exhibit adequate 
material strength to withstand the mechanical in vivo environment. MSCs, which were 
first seeded on scaffolds, have been effectively transplanted into cartilage defects, 
yielding improved results both arthroscopically and histologically (Wakitani, Imoto et al. 
2002, Wakitani, Mitsuoka et al. 2004). These scores also correlate with reported 
improvements in clinical symptoms, mainly pain and walking ability (Wakitani, 
Mitsuoka et al. 2004). It is important to note that OA induced by trauma is different from 
the cartilage degradation seen in the pathogenesis of OA, as areas of trauma are 
surrounded by healthy cartilage, which may interact differently with MSCs (Mazor, 
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Lespessailles et al. 2014). More generalized cartilage lesions and joint inflammation are 
present in OA, limiting the usefulness of focal treatments for this disease.  
Intra-articular injections of MSCs have been used to address the more peripheral 
effects of the OA phenotype (van Buul, Villafuertes et al. 2012). Synovial joints are well 
suited for local delivery of treatments via intra-articular injections due to the nature of 
their discrete cavities. The local administration of treatment means provides several 
advantages, over systemic administration, such as: increased bioavailability, reduced 
systemic exposure and fewer off-target effects (Evans, Kraus et al. 2014). Intra-articular 
injections of three-dimensional (3D) biodegradable scaffolds in polyglycolic acid mesh 
and collagen I hydrogel, seeded with MSCs, have shown hyaline cartilage regeneration in 
animal models (Cui, Wu et al. 2009, Marquass, Schulz et al. 2011). These scaffolds are a 
key component of the efficacy of these intra-articular treatments as MSCs injected intra-
articularly in a saline vehicle have been shown to exhibit decreased cell counts 
immediately following a single injection. Total clearance of these scaffold free cell 
injections has occurred in 7 days (Ozeki, Muneta et al. 2016). These results indicate a 
single injection of scaffold free MSCs is unlikely to overcome the long-term pathology of 
OA and that some form of biocompatible scaffold is necessary (ter Huurne, Schelbergen 
et al. 2012).  
In the development of various therapeutic strategies, low porosity sodium alginate 
capsules have been used as a vehicle to encapsulate various cell types for delivery to 
target areas (Orive, Hernández et al. 2003). Sodium alginate is commonly used for the 
development of microcapsules as alginate is an inert hetero-polysaccharide that is 
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commercially available (Augst, Kong et al. 2006). Under appropriate reaction conditions, 
sodium alginate will form porous capsules (Ziegelhoeffer, Fernandez et al. 2004). The 
porosity of the capsules facilitates the diffusion of metabolic agents and other nutrients 
from damaged tissues to intrascapular cells. If these cells are MSCs, this technique allows 
them to respond accordingly and communicate with native cells in their local 
environment via paracrine mechanisms (Figure 2) (Landázuri, Levit et al. 2016).  
 
Figure 2. Illustration dEPICts benefits of encapsulating hMSCs with sodium alginate. 
The mechanical barrier created by the capsule protects cells from the cells of the immune 
system along with immunoglobulins. The porosity of the capsule permits hMSCs to 
utilize their paracrine signaling properties to interact with the cells of the native tissue 
(Boyer 2015).    
 
Semi-permeable capsules have been shown to enhance cell survival, by ensuring 
cell retention within the capsules while providing a blockade to the host immune system 
(Landázuri, Levit et al. 2016). Capsule porosity has been quantified in previous studies 
and has been shown to prevent proteins over 180 kDa from entering the capsule (Levit, 
Landázuri et al. 2013). This mechanistic barrier insulates MSCs from components of the 
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immune system such as immunoglobulins and inflammatory cells, further enhancing the 
survival of these cells (Figure 2) (Landázuri, Levit et al. 2016).  
Increased MSC retention due to encapsulation can be accredited to the size of the 
capsules, which at 100 – 200 μm, prohibit the clearance of these constructs by 
phagocytosis, cellular migration and lymphatic or venous drainage (Levit, Landázuri et 
al. 2013). Encapsulated cells have been shown to yield 50-70% retention of cells 
following intra-articular injections at 2 weeks (Leijs, van Buul et al. 2016). Previous 
studies have also demonstrated that encapsulated MSCs retain their stem cell 
characteristics in vivo, as their immunophenotypic profile and differentiation profiles 
remain unchanged (Landázuri, Levit et al. 2016). Therefore, encapsulation of MSCs 
appears to amplify the therapeutic efficacy of these stem cells treatments. This study will 
implore the use of bone marrow derived human Mesenchymal Stem Cells (hMSC) to 
study the therapeutic efficacy of MSCs on OA. 
Specific Aims  
 There are currently many ongoing clinical trials using MSCs, but these have yet to 
translate into an effective therapy clinically. On the pre-clinical side, MSCs repeatedly 
show great promise. This disconnect motivates more detailed investigations into the 
mechanism of action of MSCs. Particularly, the role of paracrine action versus direct 
cellular integration of these cells need to be explored more in order to rationally design a 
therapeutic to translate to the human scale. The overall goal of this study is to examine 
the cartilage degradation and associated secondary pathological changes that occur in a 
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rat OA model with and without delivery of encapsulated hMSCs. Furthermore, we aim to 
assess the associated paracrine-mediated processes of hMSCs in this disease model. Our 
overall hypothesis is that encapsulated hMSCs will have a positive effect, via paracrine-
mediated action, on the onset and development of OA. Our aims in addressing this 
hypothesis are:  
 
Specific Aim I. Determine the effects of encapsulation on the retention of hMSCs in 
the hindlimb knee joint of a rat. We hypothesized that the encapsulation of hMSCs 
within sodium alginate capsules would increase the retention of hMSCs in the knee joint 
space. NIR labeled polystyrene beads were used to assess the retention profile of the 
sodium alginate capsules. The effects of encapsulation on retention in the knee joint 
space were tested in vivo using NIR imaging.  
 
Specific Aim II. Investigate the efficacy of intra-articular injections of encapsulated 
hMSCs for treatment of OA. We hypothesized that encapsulated hMSCs delay the 
progression of OA through their paracrine signaling mechanisms. Encapsulation of 
hMSCs allows for a delineation to be made between the contribution of soluble factors 
secreted by hMSCs and that of direct hMSC integration into the surrounding native 
tissue. OA was induced in rats via MMT surgery and encapsulated hMSCs were 
delivered via intra-articular injection. To determine the effects of the proposed treatment 
on different stages of OA, two separate protocols were implemented to investigate the 
effects of the agent on the onset of OA and the effects of the agent after OA had already 
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developed. Treatment efficacy was assessed by analysis of the micro-structural changes 
of the articular cartilage, mineralized osteophytes and subchondral bone using contrast 
enhanced microCT.  
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METHODS 
Surgical Methods 
A surgical instability animal model, medial meniscal tear (MMT), was used to 
induce OA in rats (Janusz, Bendele et al. 2002). The study of disease pathologies in 
animal models is essential as the study of OA pathology and the efficacy of different 
therapeutics in humans is challenging due to limited access to appropriate imaging 
evaluation tools and diseased tissues at different stages of disease development (Thote, 
Lin et al. 2013, Little and Smith 2008). The MMT pre-clinical model has been developed 
as a platform to evaluate disease pathology and assess the efficacy of numerous 
treatments as it has been developed for consistency, reproducibility and its likeness to 
human pathology (Bendele 2001). In this preclinical model, the phenotypical cartilage 
degradation associated with OA has been shown to present at 3 weeks post op (Janusz, 
Bendele et al. 2002). Wild type male Lewis rats (Charles River Laboratories, 
Wilmington, MA), weight matched at 275 – 300 g, were acclimated for 1 week before 
surgery. Animals were anesthetized using isoflurane and the skin over the medial aspect 
of the left femoro-tibial joint was shaved and sterilized. Blunt dissection was used to 
expose the medial collateral ligament (MCL), which was transected to access the 
meniscus. A full thickness cut was made through the meniscus at its narrowest point. 
Following meniscal transection, the skin was closed using 4.0 Vicryl sutures and stapled 
with wound clips. Sham surgery was also performed in rats, with the transection of the 
MCL followed by suturing of the joint without transection of the meniscus.  
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For the 3-week study, intra-articular injections for treatment delivery were 
utilized 1 day post-surgery, using a 25-gauge needle for 50 μL injections. The 3-week 
study assessed the efficacy of immediate hMSC treatment, as the injection was delivered 
prior to the initiation of OA. This study aimed to assess treatment efficacy on the onset of 
OA. For the immediate treatment 3-week study, four separate groups were included: 
sham, HBSS (saline) injection, empty capsule injection and encapsulated hMSC 
injection. hMSCs were sourced from the bone marrow of numerous healthy patient 
donors provided by Emory Personalized Immunotherapy Center (Emory University 
School of Medicine, Atlanta, GA) and expanded in vitro. Five million hMSCs, at passage 
5, were suspended in 1 mL of 1% ultrapure low-viscosity sodium alginate LVG 
(Novamatrix, Sandvika, Norway). Encapsulation was achieved using an electrostatic 
encapsulator (Nisco, Zurich, Switzerland) with a 0.20 mm nozzle, a 5 mL/h flow rate and 
a 7-kV voltage. Animals were euthanized at 3 weeks post-surgery via CO2 inhalation.   
For the 6-week study, intra-articular injections were utilized 3 weeks post-
surgery. The 6-week study assessed the efficacy of a delayed hMSC treatment as the 
injection was delivered following the establishment of OA. This study aimed to assess 
treatment efficacy after OA had developed. For the delayed treatment study, four study 
groups were used: 3 week MMT, sham, saline (Lactated Ringers USP) injection and 
encapsulated hMSC injection. A group was included for the takedown of MMT induced 
animals at 3 weeks to assess the state of OA induction in the animals at this time point.  
All other animals were euthanized 6 weeks post-surgery. The experimental design of the 
two respective MMT studies is outlined in the table below (Table 1).   
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Table 1. Experimental design for MMT studies. 
Immediate Treatment Study: 3-Week MMT Study 
Groups (n = 5) Sham 
MMT +  
Empty Capsule 
@ 1 Day Post-Op 
MMT +  
HBSS 
@ 1 Day Post-Op 
MMT +  
Encapsulated hMSC 
@ 1 Day Post-Op 
Delayed Treatment Study: 6-Week Study 
Groups (n = 4-5) Sham  
MMT + 
No injection 
(3 week takedown) 
MMT +  
Saline 
@ 3 Weeks Post-Op 
MMT +  
Encapsulated hMSC 
@ 3 Weeks Post-Op 
 
Following euthanasia in both studies, left hindlimbs were collected for further 
analysis. Contralateral controls, collected from right hind limbs (n=3), were also collected 
to assess for phenotypic changes incurred in naïve animals out to each of the respective 
study time points. Animal care and experiments were conducted in accordance with the 
institutional guidelines of the Atlanta VA Medical Center and Emory University School 
of Medicine.  
Retention Profile Analysis  
 Retention of intra-articularly injected sodium alginate capsules was assessed in 
the knee of rat hindlimbs using NIR imaging. FluoSphere Carboxylate-Modified 
Microspheres, Infrared (Thermo Fisher Scientific, Waltham, MA) were encapsulated in 
sodium alginate in the same manner hMSCs were encapsulated. Naïve Lewis rats (n=2) 
were injected intra-articularly with 50 μL encapsulated FluoSpheres using a 25-gauge 
needle. A Bruker In-Vivo Xtreme (Bruker, Billerica, MA) was used for NIR imaging and 
was carried out for 9 weeks. All images were exposed to an excitation wavelength of 730 
nm and an emission wavelength of 790 nm for 0.5 sec of exposure time.  Fluorescent 
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intensity values were quantified using ImageJ software. Intensity values were plotted as 
percent of the maximum intensity.  
EPIC-μCT Analysis of OA Induced Structural Changes 
 Articular cartilage, osteophyte and subchondral bone structure and composition 
were quantitatively evaluated on the medial tibial plateau in accordance with previous 
established protocols (Thote, Lin et al. 2013). Scanco evaluation software permitted the 
assessment of both 3D morphological parameters as well as local attenuation. Collected 
hind limbs were fixed in 10% neutral buffered formalin for 48 hours before the tibia were 
dissected out exposing the articular cartilage of the medial tibial plateau. Dissected tibia 
were stored in PBS until scans were run. Directly before scanning, tibia were immersed 
in 2 mL of 30% HexabrixTM contrast reagent (Guerbet, Villepinte, France) and 70% PBS 
at 37 °C for 30 minutes (Palmer, Guldberg et al. 2006). Hexabrix was utilized as an ionic 
computed tomography (CT) agent before μCT scanning to compensate for the poor 
radiopacity of the nonmineralized articular cartilage surfaces (Palmer, Guldberg et al. 
2006). Samples were then scanned using a μCT 40 (Scanco Medical, Brüttisellen, 
Switzerland) with the following established inputs for cartilage scans: 45 kVp, 177 µA, 
200 ms integration time and a voxel size of 16 µm (Xie, Lin et al. 2009). The 3D images 
generated from the scans were delimited into four separate volumes of interest (VOI): full 
articular cartilage of the proximal medial tibia, medial 1/3 of the proximal medial tibia, 
mineralized osteophyte of the most medial aspect of the medial tibial condyle and 
subchondral bone of the medial tibial condyle.   
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 The articular cartilage surface of the medial tibial plateau was contoured and 
thresholded (Figure 3) with the following parameters: Gauss sigma – 1.0, gauss support – 
1, threshold 95 – 310. Parameters for the total cartilage and medial 1/3 cartilage included 
volume, thickness and attenuation. Medial 1/3 articular cartilage was analyzed as this 
region has previously been cited as a region of high damage incidence in the MMT OA 
model (Thote, Lin et al. 2013). The cartilage attenuation parameter is a quantitative 
value, which is inversely proportional to the sulfated glycosaminoglycan (sGAG) 
concentration (Palmer, Guldberg et al. 2006). Hexabrix is a negatively charged hexa-
iodinated dimer, which allows for the exploitation of the electrochemical interactions that 
occur in articular cartilage. OA progression results in sGAG loss, which induces a new 
equilibrium state between negatively charged sGAG and Hexabrix, which can be 
quantified to assess sGAG concentration. Degraded cartilage expresses lower sGAG 
content and therefore a higher contrast reagent, Hexabrix, concentration in the articular 
cartilage.    
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Figure 3. Representative EPIC-μCT images illustrating contours of total cartilage and 
medial 1/3 cartilage of the articulating surface of the medial tibial condyle. Contours 
were thresholded to only include articular cartilage, in the VOI, in the evaluations run for 
articular cartilage volume, thickness and attenuation for each of the respective volumes of 
cartilage.      
 
The mineralized osteophyte volume on the most medial aspect of the medial tibial 
condyle was contoured and thresholded (Figure 4) based on the same energy and 
integration parameters as the articular cartilage evaluation but with a threshold of 270 – 
435 used. Natural contours of the bone were assessed by scrolling forwards and 
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backwards through adjacent scanned sections to accurately identify mineralized 
osteophytes.  
 
Figure 4. Representative EPIC-μCT images illustrating contours of mineralized 
osteophytes on the most medial aspect of the medial tibial condyle. Contours were 
thresholded to only include mineralized osteophyte, in the VOI, in the evaluations run for 
volume.  
 
 The subchondral bone of the medial tibial condyle was contoured and thresholded 
(Figure 5) based on the same settings used for articular cartilage but with threshold 
settings of 290 – 1000. Parameters for the evaluation of the subchondral bone included: 
volume, thickness, attenuation and porosity. Porosity of the subchondral bone was 
calculated using the following formula: 1 – (Bone Volume/Total Volume) (Xie, Lin et al. 
2012).  
 20 
 
Figure 5. Representative EPIC-μCT images illustrating contours of the subchondral bone 
of the medial tibial condyle. Contours were thresholded to only include subchondral 
bone, in the VOI, in the evaluations run for bone volume, thickness, attenuation and 
porosity. 
Surface Roughness Analysis of Articular Cartilage  
 The surface roughness of the articular cartilage of the medial tibial condyle was 
assessed using a MATLAB script that assessed sample images rendered from the EPIC-
μCT scans. The parameters of the articular cartilage that were assessed included: surface 
roughness, lesion volume and exposed bone volume. The surface roughness parameter 
analyzed damage and fibrillations of the cartilaginous surfaces. Lesions were identified as 
depressions in the cartilage surfaces that were 25% or greater of the total cartilage 
thickness. The exposed bone parameter quantified the volume of subchondral bone 
exposed as a result of full cartilage degradation of the articulating surface on the medial 
tibial condyle.  
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Statistical Analysis  
All quantitative data were expressed as mean ± standard deviation (SD). Joint 
parameters between MMT groups were evaluated using a one factor ANOVA with a post 
hoc Tukey’s HSD test to identify differences between respective groups. The 
Contralateral group was compared with the Sham using an unpaired two-way t-test. No 
comparisons were assessed between the Contralateral group and any of the MMT groups. 
For the 6-week study, the one factor ANOVA was run between only groups carried out to 
the 6-week time point, which excluded the 3 week MMT control. Joint parameters, 
including multiple time points and multiple MMT groups were evaluated using a two 
factor ANOVA with post hoc Tukey HSD test. Differences for the lesion volume and 
exposed bone parameter were assessed using a one factor ANOVA with a non-parametric 
post hoc Kruskal Wallis test. Statistical significance was set at p < 0.05. All data were 
analyzed using GraphPad Prism software version 6.0 (GraphPad Software, Inc., La Jolla, 
CA).  
  
 22 
RESULTS 
Intra-Articular Retention Profile of Sodium Alginate Capsules 
The retention profile of sodium alginate capsules was assessed using encapsulated 
NIR FluoSphere Carboxylate-Modified Microspheres for 9 weeks using NIR imaging. A 
one-phase exponential decay model (R2 = 0.9926) was used to quantify the clearance 
kinetics of the FluoSpheres from the knee space. Intra-articular injections of sodium 
alginate capsules yielded a half-life of 7.958±1.481 days and a time constant (tau) of 
11.48±2.14 days (Figure 6). The time constant utilizes initial and final fluorescence 
intensity values to determine the amount of time it takes the maximum fluorescence 
intensity to reach 36.8% of its original value. The half-life value represents the amount of 
time it takes the initial fluorescence intensity to reach 50% of its original value. The 
absence of complete clearance in this study lends to using the time constant value over 
the half-life, as the half-life parameter assumes complete clearance. Qualitative data in 
the form of representative images are included to further qualify the retention profile of 
the sodium alginate capsules used for cellular encapsulation in the study (Figure 6).     
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Figure 6. Retention profile of sodium alginate capsules assessed using NIR labeled 
sodium alginate capsules (n=2). NIR labeled capsules were intra-articularly injected into 
the knee joint of the left hind limb of naïve Lewis Rats. Fluorescent readings were 
quantified and plotted based on the percent maximum intensity of the highest fluorescent 
reading, which occurred at the 0-Day time point. Representative images are displayed 
below the figure, showing fluorescent intensity overlaid on X-Ray images of the left hind 
limb.   
Immediate Treatment 3-Week Study 
 The treatment efficacy of encapsulated hMSCs on delaying the onset of OA was 
assessed in the 3-week MMT study. Cartilage structure and composition of the collected 
tibia samples were evaluated using EPIC-μCT for volume, thickness and attenuation 
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parameters, for both the total medial tibial condyle articular cartilage surfaces as well as 
the medial 1/3 cartilage volume. All of the values for each of these parameters are 
expressed as mean ± SD (Table 2).  
Table 2. EPIC-μCT analysis of articular cartilage parameters for 3-week MMT study.   
Total Medial Tibial Plateau Articular Cartilage 
  
Volume 
(mm3) 
Thickness 
(mm) 
Attenuation 
(mg HA/cm3) 
Contralateral 0.9211±0.130 0.1925±0.00580 281.6±16.0 
Sham 1.045±0.0732 0.1813±0.0222 293.0±15.8 
MMT/Empty 1.222±0.0719 0.1999±0.00701 335.9±15.5 
MMT/HBSS 1.287±0.0850 0.2115±0.00549 325.7±16.7 
MMT/hMSC 1.209±0.0775 0.2033±0.00837 326.4±10.9 
Medial 1/3 Medial Tibial Plateau Articular Cartilage 
  
Volume 
(mm3) 
Thickness 
(mm) 
Attenuation 
(mg HA/cm3) 
Contralateral 0.1996±0.0513 0.09342±0.0384 269.4±16.8 
Sham 0.2530±0.0269 0.1266±0.0131 299.9±24.4 
MMT/Empty 0.3190±0.0717 0.1465±0.0134 340.4±20.5 
MMT/HBSS 0.3879±0.0253 0.2018±0.0127 337.2±22.6 
MMT/hMSC 0.3498±0.0101 0.1788±0.0132 338.1±33.1 
 
A significant difference was detected between the Sham and both the HBSS and 
hMSC groups for cartilage thickness, as both groups showed increased cartilage 
thickness, on the medial 1/3 of the tibial plateau. The only significant difference detected 
between individual MMT groups was for the Empty Capsule group and the HBSS group. 
Even though there was no difference detected between the HBSS group and the hMSC 
group, the hMSC group does trend towards decreased cartilage thickness. No difference 
 25 
was detected between the Sham and the Contralateral for differences in thickness of the 
articular cartilage surface (Figure 7).  
 
Figure 7. Medial 1/3 cartilage thickness of the articulating surface of the medial tibial 
condyle for the immediate treatment 3-week study. MMT/HBSS and MMT/hMSC had 
significantly higher cartilage thickness then the Sham. MMT/HBSS had a significant 
increase in cartilage thickness in comparison to MMT/Empty. ** = p ≤ 0.01, **** = p ≤ 
0.0001, n (Sham and MMT Groups) = 5, n (Contralateral) = 3.    
 
Cartilage attenuation is a quantitative value, which is inversely proportional to the 
sGAG concentration of the articular cartilage. Quantification of this parameter showed no 
differences between each of the respective MMT groups. However, a significant 
difference was detected between the Sham group and each of the three MMT groups: 
Empty Capsule, HBSS and hMSC. The increased attenuation yielded in each of these 
groups is suggestive of a decreased sGAG concentration in the articular cartilage. There 
was no difference detected between the Sham and the Contralateral groups (Figure 8).   
 26 
 
Figure 8. Medial cartilage attenuation of the articulating surface of the medial tibial 
condyle for the immediate treatment 3-week study. All MMT conditions: Empty, HBSS 
and hMSC had increased cartilage attenuation in comparison to Sham group. * = p ≤ 
0.05, ** = p ≤ 0.01, n (Sham and MMT Groups) = 5, n (Contralateral) = 3.    
 
The surface of the articular cartilage of the medial tibial condyle was assessed 
using MATLAB script to evaluate images rendered by the EPIC-μCT. In quantifying 
surface roughness, a significant difference was found between the Sham group and 
Empty Capsule and HBSS groups, but not between the Sham and hMSC groups. Further, 
a significant difference was detected between the hMSC group and the Empty Capsule 
and HBSS groups for the roughness of the cartilage surfaces, with the hMSC group 
yielding a decreased surface roughness. No difference was detected between the Sham 
and Contralateral groups for this parameter (Figure 9).   
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Figure 9. Medial cartilage surface roughness of the articulating surface of the medial 
tibial condyle for the immediate treatment 3-week study. MMT/Empty and MMT/HBSS 
had significantly higher cartilage surface roughness then the Sham. MMT /Empty and 
MMT/HBSS had a significant increase in cartilage surface roughness in comparison to 
MMT/hMSC. * = p ≤ 0.05, ** = p ≤ 0.01, n (Sham and MMT Groups) = 5, n 
(Contralateral) = 3.    
 
Lesion volume, which defines abrasions in the articular cartilage surface that are 
greater than or equal to 25% of the total cartilage thickness, were quantified for all groups 
in the 3-week study. The Sham and hMSC groups showed close to zero lesion volume, 
with a few samples yielding very small volumes. Empty Capsule and HBSS groups 
showed increases in lesion volume compared to the Sham and hMSC groups, but had 
high data variability. The Contralateral showed zero lesion volume and yielded no 
differences in comparison to Sham (Figure 10).  
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Figure 10. Lesion volume of the cartilage on the articulating surfaces of the medial tibial 
plateau for the immediate treatment 3-week study. No differences were detected between 
any of the MMT conditions or for any MMT conditions compared to the Sham. n (Sham 
and MMT Groups) = 5, n (Contralateral) = 3. 
 
Mineralized osteophyte volume of the most medial aspect of the medial tibial 
condyle was quantified via EPIC-μCT. The osteophyte volume for all MMT conditions 
showed increased mineralization volume in comparison to Sham. The only significant 
differences detected between the three individual MMT induced conditions occurred 
between the Empty Capsule and hMSC groups, with the hMSC group yielding a higher 
volume. The Sham and Contralateral groups showed only very small mineralized 
osteophyte volume with no differences detected between the two. The hMSC group did 
not yield a significant difference in volume compared to the HBSS group, but did show a 
trend towards increased volume for mineralized osteophyte (Figure 11).   
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Figure 11. Mineralized osteophyte volume of the most medial aspect of the medial tibial 
condyle for the immediate treatment 3-week study. All MMT groups had significantly 
higher mineralized osteophyte volume then the Sham. MMT /hMSC had a significant 
increase in volume in comparison to the Sham. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001, **** = p ≤ 0.0001, n (Sham and MMT groups) = 5, n (Contralateral) = 3. 
 
The subchondral bone of the medial tibial condyle was assessed using EPIC-μCT 
for volume, thickness, attenuation and porosity parameters. All the values for each of 
these parameters are expressed as mean ± SD (Table 3). 
Table 3. EPIC-μCT analysis of subchondral bone parameters for 3-week MMT study. 
Medial Tibial Condyle Subchondral Bone 
 Volume 
(mm3) 
Thickness 
(mm) 
Attenuation 
(mg HA/cm3) 
Porosity 
(PU) 
Contralateral 1.268±0.0321 0.1969±0.00800 1069±15.8 0.05323±0.0123 
Sham 1.143±0.0479 0.1769±0.00740 1092±8.75 0.07494±0.0153 
MMT/Empty 1.270±0.105 0.2041±0.0189 1121±16.9 0.05892±0.0191 
MMT/HBSS 1.341±0.0637 0.2026±0.00728 1124±4.64 0.06039±0.00860 
MMT/hMSC 1.291±0.0543 0.1976±0.00841 1121±10.7 0.06715±0.00194 
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Both the HBSS and hMSC groups showed increased subchondral bone thickness 
compared to the Sham. However, there was not a significant difference detected between 
the Empty Capsule group and the Sham, but the Empty Capsule group did show 
increased data variability. No differences were detected between each of the respective 
MMT groups. The Sham did show a decrease in the thickness of the subchondral bone 
compared to the Contralateral group (Figure 12).  
 
Figure 12. Subchondral bone thickness of the medial tibial plateau for the immediate 
treatment 3-week study. The MMT/HBSS and MMT/hMSC groups showed significantly 
higher subchondral bone thickness in comparison to the Sham. The Sham did show a 
decrease in subchondral bone thickness in comparison to the Contralateral control. * = p 
≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, n (Sham and MMT Groups) = 5, n (Contralateral) 
= 3. 
 
Qualitative assessment for each of the quantitative parameters analyzed above can 
be carried out through analyzing the representative images for the Sham, Empty Capsule, 
HBSS and hMSC groups (Figure 13). Parameters that are best highlighted by these 
images include: surface roughness, lesion volume and mineralized osteophyte volume.  
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Figure 13. Representative coronal attenuation maps of medial tibial condyle for Sham 
and MMT groups of the immediate treatment 3-week study. Red displays high 
attenuation values, low sGAG concentrations and green displays low attenuation values, 
high sGAG concentrations. An inverse relationship exists between attenuation and sGAG 
concentration. Arrows in white identify regions with high surface roughness and lesions. 
Arrows in grey identify regions with mineralized osteophytes. 
Delayed Treatment 6-Week Study 
 The treatment efficacy of encapsulated hMSCs on disease progression following 
OA initiation was assessed in the 6-week MMT study. Cartilage structure and 
composition of the collected tibia samples were evaluated using EPIC-μCT for volume, 
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thickness and attenuation parameters for both the total medial tibial condyle articular 
cartilage surfaces as well as the medial 1/3. All the values for each of these parameters is 
expressed as mean ± SD (Table 4).  
Table 4. EPIC-μCT analysis of articular cartilage parameters for 6-week MMT study. 
Total Medial Tibial Plateau Articular Cartilage 
  
Volume 
(mm3) 
Thickness 
(mm) 
Attenuation 
(mg HA/cm3) 
3W 1.064±0.137 0.1644±0.0194 330.6±13.2 
6W CL 0.8572±0.134 0.1323±0.0107 287.7±11.1 
6W Sham 1.003±0.0935 0.1713±0.00577 341.9±28.7 
6W Saline 1.183±0.181 0.1728±0.0262 328.9±19.3 
6W hMSC 1.185±0.0964 0.1745±0.0127 324.3±9.96 
Medial 1/3 Medial Tibial Plateau Articular Cartilage 
  
Volume 
(mm3) 
Thickness 
(mm) 
Attenuation 
(mg HA/cm3) 
3W 0.2125±0.0817 0.1260±0.0261 313.1±31.0 
6W CL 0.1749±0.0281 0.08133±0.0130 276.1±16.2 
6W Sham 0.2124±0.0602 0.1023±0.0155 330.0±26.6 
6W Saline 0.2916±0.132 0.1630±0.0622 322.6±35.8 
6W hMSC 0.3048±0.0116 0.1473±0.0180 312.5±28.5 
 
Quantification of cartilage thickness of the medial 1/3 of the medial tibial condyle 
yielded only a single significant difference, between the Sham and hMSC group. The 
Saline group trended towards an increased thickness in comparison to the Sham, but had 
a high variability in the data. The Contralateral and Sham groups showed no differences 
in cartilage thickness (Figure 14). In comparison to the 3-week study (Figure 7), for the 
Saline and hMSC groups specifically, we see similar trends for increased thickness in the 
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two groups compared to the Sham. However, we see decreased cartilage thickness in the 
6-week study compared to the 3-week study, with values of 0.2017±0.0127 mm and 
0.1788±0.0132 mm at 3 weeks (Figure 7) and values of 0.1630±0.0622 mm and 
0.1473±0.0180 mm at 6 weeks (Figure 14) for the Saline and hMSC groups, respectively.  
 
Figure 14. Medial 1/3 cartilage thickness of the articulating surface of the medial tibial 
condyle for the delayed treatment 6-week study. 6W hMSC had significantly higher 
cartilage thickness then the 6W Sham. ** = p ≤ 0.01, n (MMT groups) = 5, n (Sham) = 4, 
n (Contralateral) = 3.   
 
 Cartilage attenuation is a quantitative value, which is inversely proportional to the 
sGAG concentration of the articular cartilage. In quantifying the attenuation of the total 
cartilage for the medial tibial condyle, values for the 6-week groups: Sham, Saline and 
hMSC had very similar attenuation values, showing no differences. The Sham group at 6 
weeks yielded attenuation values that were similar to the MMT control group that was 
taken down at 3 weeks. The increased attenuation yielded in the Sham group suggests a 
decreased sGAG concentration in the articular cartilage, due to the inverse relationship 
that exists between the concentration of sGAG and attenuation values. The decreased 
sGAG concentration of the Sham is further supported by the significant difference 
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detected with the Contralateral group (Figure 15). In the immediate treatment 3-week 
(Figure 8) study, the Sham and Contralateral groups had similar attenuation values with 
no differences existing between the two.   
 
Figure 15. Medial cartilage attenuation of the articulating surface of the medial tibial 
condyle for the delayed treatment 6-week study. No differences were detected between 
any of the MMT groups or between any MMT group and the Sham. A single difference 
was detected though between the Sham and Contralateral groups. ** = p ≤ 0.01, n (MMT 
Groups) = 5, n (Sham) = 4, n (Contralateral) = 3.    
 
The surface of the articular cartilage of the medial tibial condyle was assessed 
using MATLAB script to evaluate images rendered by the Scanco μCT40. Values for 
surface roughness yielded significant differences between the Sham and Saline groups as 
well as between Saline and hMSC groups. The surface roughness of the hMSC group was 
similar to that of the Sham group. The value for the Sham group was higher than reported 
for the immediate treatment 3-week study (Figure 9), which yielded a surface roughness 
of 16.24 μm, compared to that of the 6-week study with a value of 19.62 μm. This 
increased surface roughness of the Sham group is further supported by the increased 
value yielded in comparison to the Contralateral control group (Figure 16).  
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Figure 16. Medial cartilage surface roughness of the articulating surface of the medial 
tibial condyle for the delayed treatment 6-week study. The 6W Saline group had 
significantly higher surface roughness values then both the 6W Sham and 6W hMSC 
groups. * = p ≤ 0.05, ** = p ≤ 0.01, n (MMT groups) = 5, n (Sham) = 4, n (Contralateral) 
= 3.    
 
 Exposed bone area was quantified for all groups in the 6-week study. The Saline 
group trended towards the largest amount of exposed bone compared to all other groups, 
but did have a high variability of the data set with one sample showing greater than 0.024 
μm2 of exposed bone area. The hMSC group trended towards less exposed bone area on 
average compared to the Saline group, but also had high data variability as three of the 
five total samples in the group did not show any exposed bone at all. The Contralateral 
and Sham groups yielded no exposed bone volume (Figure 17).  
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Figure 17. Exposed bone volume on the plateau of the medial tibia for the delayed 
treatment 6-week study. No differences were detected between any of the MMT 
conditions or between any MMT group and the Sham. n (MMT Groups) = 5, n (Sham) = 
4, n (Contralateral) = 3. 
 
The mineralized osteophyte volume of the most medial aspect of the medial tibial 
condyle was quantified using EPIC-μCT. The osteophyte volume for both 6-week MMT 
conditions showed increased mineralization volume in comparison to Sham. The hMSC 
yielded a significantly increased mineralized osteophyte volume in comparison to the 
Saline group. The Sham and Contralateral groups showed only very small mineralized 
osteophyte volume, with no differences detected between the two.  Additionally, the 3-
week MMT control showed a trend towards increased mineralized osteophyte volume 
(Figure 18), which is in accordance with the osteophyte data from the immediate 
treatment 3-week study.  
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Figure 18. Mineralized osteophyte volume of the most medial aspect of the medial tibial 
condyle of the delayed treatment 6-week study. All MMT groups had significantly higher 
mineralized osteophyte volume then the Sham. MMT /hMSC had a significant increase in 
volume in comparison to the MMT/Saline group. **** = p ≤ 0.0001, n (MMT Groups) = 
5, n (Sham) = 4, n (6W Contralateral) = 3. 
 
 The data from the immediate treatment (3-week) and delayed treatment (6-week) 
MMT studies were combined to assess the volume of mineralized osteophytes in the 
three study groups which were consistent between the two studies: Sham, Saline (denoted 
by HBSS in 3W study) and hMSC.  The data for each of the respective time point studies 
parallel the 3-week (Figure 11) and 6-week (Figure 18) osteophyte data sets. Samples are 
not uniform between each group represented as each point represents unique samples 
collected for each of the respective MMT studies. For the initial time point, an 
assumption that the osteophyte volume was equal to 0 was made. In assessing significant 
differences between each of the groups with respect to both mineralized osteophyte 
volume and time, both the Saline and hMSC groups showed significant differences 
compared to the Sham. Additionally, the hMSC group yielded an increased osteophyte 
volume, over the respective time course, in comparison to the Saline group (Figure 19).    
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Figure 19. Mineralized osteophyte volume of the most medial aspect of the medial tibial 
condyle for both 3-week and 6-week studies. Both MMT groups had significantly higher 
mineralized osteophyte volume then the Sham over the course of both studies. MMT 
/hMSC had a significant increase in volume in comparison to the MMT/Saline group. ### 
= p ≤ 0.001, **** = p ≤ 0.0001. 
   
The subchondral bone of the medial tibial condyle was assessed using EPIC-μCT 
for volume, thickness, attenuation and porosity parameters. All the values for each of 
these parameters are expressed as mean ± SD (Table 5).  
Table 5. EPIC-μCT analysis of subchondral bone parameters for 6-week MMT study. 
Medial Tibial Condyle Subchondral Bone 
  
Volume  
(mm3) 
Thickness  
(mm) 
Attenuation  
(mg HA/cm3) 
Porosity 
(PU) 
3W 1.244±0.0471 0.1957±0.00397 1124±13.4 0.04460±0.00351 
6W CL 1.167±0.0101 0.1926±0.00219 1112±6.09 0.04322±0.00272 
6W Sham 1.087±0.0615 0.1737±0.00310 1119±15.3 0.04081±0.00679 
6W Saline 1.213±0.0684 0.1987±0.00877 1139±12.1 0.0391±0.0120 
6W hMSC 1.208±0.0738 0.1986±0.00991 1144±24.0 0.02960±0.00792 
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There were no differences detected between the respective groups for subchondral 
bone porosity, but there were trends that could be extrapolated from the data. The 3 week 
MMT control, Contralateral control and Sham groups showed no significant differences 
in bone porosity. The implication of any trends in the Sham, Saline and hMSC groups are 
hard to denote due to the variability of the data sets, but the hMSC group showed a trend 
towards decreased subchondral bone porosity (Figure 20).  
 
Figure 20. Subchondral bone porosity of the medial tibial plateau for the delayed 
treatment 6-week study. No differences were detected between any of the study groups. n 
(MMT Groups) = 5, n (Sham) = 4, n (Contralateral) = 3. 
 
 Qualitative assessment for each of the quantitative parameters analyzed above can 
be carried out through analyzing the representative images for the 3W MMT control, 6W 
Sham, 6W Saline and 6W hMSC groups (Figure 21). Parameters that are best highlighted 
by these images include: surface roughness, exposed bone area and mineralized 
osteophyte volume.  
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Figure 21. Representative coronal attenuation maps of medial tibial plateau for Sham and 
MMT groups of the delayed treatment 6-week study. Red displays high attenuation 
values, low sGAG concentrations and green displays low attenuation values, high sGAG 
concentrations. An inverse relationship exists between attenuation and sGAG 
concentration. Arrows in white identify regions with high surface roughness or exposed 
bone. Arrows in grey identify regions with mineralized osteophytes. 
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DISCUSSION 
 
There is an unmet medical need for the development of disease modifying OA 
drugs. Current OA drugs address symptomatic relief rather than modification and 
mitigation of the disease. hMSCs present a promising therapeutic option due to their 
multipotency and paracrine signaling properties. Encapsulation of hMSCs in sodium 
alginate prevents the self-integration of these cells into the native tissues and allows for 
the paracrine mechanisms of these cells to be studied directly. Previous work from other 
groups has shown that hMSCs preserve their characteristics following encapsulation and 
implantation in vivo (Landázuri, Levit et al. 2016). Paracrine-mediated processes 
involving hMSCs include the recruitment of stem and progenitor cells, prevention of 
apoptosis, facilitation of beneficial remodeling and modulation of the immune response 
(Caplan and Dennis 2006). The objective of this study was to quantitatively assess the 
efficacy of encapsulated bone marrow hMSCs as a disease modifying intervention for 
OA.  
Retention Profile of Sodium Alginate Capsules 
Intra-articular injections of MSCs have been reported in previous studies using 
preclinical animal models of OA. Previous reports have cited issues with the retention 
and viability of cells in the knee space following intra-articular injections. Total clearance 
of scaffold free cell injections occurred in 7 days, indicating that a single injection of 
scaffold free MSCs is not adequate to overcome the long-term pathology of OA (Ozeki, 
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Muneta et al. 2016). These findings suggest that some form of biocompatible scaffold 
may be necessary for efficient treatment (ter Huurne, Schelbergen et al. 2012). NIR 
imaging was used to assess the retention of NIR labeled sodium alginate capsules intra-
articularly injected into animals (Aim I). Clearance of the capsules yielded 66.4% total 
clearance with a tau value of 11.48 days. Even though retention of these capsules does 
not validate cellular viability, previous studies have shown that capsules maintain the 
viability of hMSCs at 7 days and show increased cellular viability at 14 and 21 days 
when compared to non-encapsulated hMSCs (Landázuri, Levit et al. 2016). The 
enhancement of cellular retention and viability in the knee space may yield enhanced 
therapeutic potential of hMSCs as an efficacious treatment for OA.  
Articular Cartilage Analysis 
EPIC-μCT image analysis provided a means for 3D quantitative evaluation of 
changes in articular cartilage (Aim II). For the immediate treatment 3-week study, the 
EPIC-μCT data showed a trend towards decreased cartilage thickness and a decreased 
surface roughness for the hMSC group in comparison to the HBSS group, specifically. 
The results of these two analyses speak to a potential protective role of the hMSCs on the 
articular cartilage of the medial tibial condyle. Swelling of the articular cartilage surface 
is a hallmark phenotype of early OA development, as articular cartilage swells when its 
collagen network is degraded (Summers, Merrill et al. 2008). Additionally, increased 
fibrillations of the articular cartilage are another phenotype of early OA. These 
fibrillations are a result of the enhanced production of proteoglycan and cartilage by 
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chondrocytes in response to initial cartilage loss (Martel-Pelletier 2004). These two 
phenotypes can be directly associated with the two analytic parameters of cartilage 
thickness and surface roughness, respectively. To further support this claim, the lesion 
volume for articular cartilage in the 3-week study trended towards a decrease in the 
hMSC group in comparison to the other two MMT groups.  
For the delayed treatment 6-week study, the trends and significant differences 
noted for the immediate treatment 3-week study were not observed. This may be a result 
of the continued progression of OA and the associated changes in the cellular 
environment of the joint. The EPIC-μCT data for the 6-week study showed a significant 
reduction of articular cartilage surface roughness for the hMSC group in comparison to 
the Saline group but no significant differences or trends were noted between the two 
respective groups for cartilage thickness. This lack of difference between the hMSC and 
Saline groups for cartilage thickness suggest that articular cartilage swelling does not 
play a prominent role in the later stages of OA.  
The articular cartilage degradation, associated with OA development, involves 
matrix fibrillation, fissure appearance, macroscopic ulceration and eventually full-
thickness loss of the articular cartilage surfaces resulting in bone on bone contact 
(Martel-Pelletier 2004). The macroscopic ulceration and full thickness loss of articular 
cartilage in the later stages of OA are supported by the trend towards decreased exposed 
bone noted in the 6-week study for the hMSC group compared to the Saline group. It is 
also important to note that exposed bone is not factored into the quantitative analysis of 
cartilage thickness, but rather is addressed in the cartilage volume parameter. The 
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increased progression in cartilage degradation, for the 6-week time point in comparison 
to the 3-week time point, is further supported by the damage seen in the Sham group of 
the 6-week study.  
The attenuation value of the Sham group for the delayed treatment study showed 
a significantly higher value than that of the Contralateral control and showed no 
differences with the MMT groups. This increase in attenuation, which corresponds with a 
decreased sGAG concentration for the Sham group, contrasts the results of the 3-week 
immediate treatment study, which yielded a significantly lower attenuation value for the 
Sham group, when compared with the other MMT conditions. These resulting differences 
are further validation of the increased damage seen in the delayed treatment study. 
Further, these results show the importance of the attenuation parameter in the immediate 
treatment 3-week study. It not only accounts for changes in proteoglycan concentration 
but provides a means to assess the success of induction of OA by MMT surgery. 
However, in the 6-week study attenuation does not yield these differences and therefore 
does not appear to be as pertinent in assessing the articular cartilage composition at this 
stage of OA.  
The chondroprotective role of intra-articularly injected MSCs has been shown in 
several studies using single, scaffold free, MSC injections (Yang, Zhu et al. 2015, ter 
Huurne, Schelbergen et al. 2012). The mechanisms behinds these therapies are still 
unclear though. Further study of the paracrine mediate processes of the hMSCs on the 
protection of the cartilaginous surfaces, during OA progression, was a major focus of this 
study.  
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Mineralized Osteophyte Analysis 
EPIC-μCT image analysis provided a means for 3D quantitative evaluation of 
changes in osteophyte volume (Aim II). Osteophytes are bony outgrowths that form on 
the margins of joints and are a hallmark phenotype of OA development. The EPIC-μCT 
data showed increased mineralized osteophyte volume in the hMSC group in comparison 
to the Sham group for both studies run. In comparing osteophyte volume between the 
hMSC and Saline groups, a trend towards increased mineralized osteophyte volume was 
found in the immediate treatment 3-week study, while a significant increase in volume 
was detected for the delayed treatment 6-week study. To further substantiate these 
findings, the osteophyte data sets were combined for each of the respective studies. 
Analysis showed increased osteophyte volumes for the hMSC group in comparison to 
both the Sham and Saline groups. Collectively, these findings suggest the importance of 
both the treatment group and the state of disease progression in the development of 
mineralized osteophytes.   
 These findings may have been a result of the numerous osteogenic factors 
released by the hMSC secretome: Bone Morphogenic Protein (BMP)-1, Osteonectin and 
IGF-1 (Kristensen, Chen et al. 2012). These bony outgrowths on the margins of the joint 
are a staple of OA development and present confounding results as it relates to the 
efficacy of hMSCs in the treatment of OA (Madry, Dijk et al. 2010). This is the first 
instance in the literature that shows hMSC injections increased the volume of mineralized 
osteophytes in animal pre-clinical models for OA.  
 46 
Subchondral Bone Analysis  
EPIC-μCT image analysis provided a means for 3D quantitative evaluation of 
changes in subchondral bone (Aim II). For the immediate treatment 3-week study, no 
differences were detected for the subchondral bone thickness or any of the other 
parameters assessed for this structural component. All 3-week MMT groups showed an 
increase in thickness, compared to the Sham, indicating an increase in subchondral bone 
sclerosis, a hallmark phenotype of OA, in each of these groups. Subchondral bone 
sclerosis, which occurs secondarily to degradation of the articular cartilage, has been 
reported as being more prevalent in more advanced stages of OA, which may explain the 
lack of differences, between MMT conditions, detected for the immediate treatment study 
(Li, Yin et al. 2013).  
For the delayed treatment 6-week study, the hMSC group trended towards a 
decreased porosity in comparison to the Saline group as well as all of the other study 
groups. This result could potentially suggest increased sclerosis of the hMSC treated 
group, but only further studies will be able to validate this trend. Increased sclerosis of 
the subchondral bone of the hMSC group may be an additional phenotypic alteration 
induced by the osteogenic factors released by the hMSC secretome. All other parameters 
of the delayed treatment study for subchondral bone, mainly bone thickness, did not show 
any differences or trends for the hMSC group in comparison to the Saline treated group. 
Both of these respective MMT groups did show trends towards higher thickness values, 
in the delayed treatment study, in comparison to the other study groups indicating 
increased subchondral bone thickness in each of these groups. Studies from other groups 
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have showed increased density of the subchondral bone in MSC treated groups, but only 
relative quantification, in the form of immunohistochemistry, has been used rather than 
the objective quantification of EPIC-μCT. These analytical differences provide additional 
challenges in comparing the results between these respective studies (Chiang, Ma et al. 
2016).  
This is one of the first studies to use sodium alginate encapsulation of hMSCs as 
an innovative scaffold means for intra-articular injections into the knee space. The use of 
these scaffolds allowed not only for enhanced cellular retention in the knee space but 
provided a means to assess the paracrine mechanisms of hMSCs on OA in a pre-clinical 
rat model. EPIC-μCT, as a quantitative analytical tool of numerous structural metrics, 
showed a potential chondroprotective role of encapsulated hMSCs in the early stages of 
OA. These advantages of encapsulated hMSCs were countered by an increase in 
secondary OA phenotypic changes, mainly increased mineralized osteophyte volume and 
a trend towards increased subchondral bone sclerosis in the later stages of OA. hMSCs 
have shown great potential as disease modifying drugs and through this study we have 
further explored the efficacy of these drugs for future treatments of OA.  
Clinical trials, with many currently ongoing, have demonstrated improvements in 
arthroscopic assessments of the knee joint space as well as significant improvements in 
patient quality of life (Wakitani, Imoto et al. 2002, Nejadnik, Hui et al. 2010). However, 
there are still more questions left unanswered then have yet to be answered with current 
scientific evidence. One major treatment component that has yet to be addressed, is the 
effect that hMSC treatments have in significantly changing the volume of cartilage on 
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these articulating surfaces (Yu and Hunter 2016). Additionally, all current trials are 
implementing scaffold free means in delivering hMSCs, which can potentially reduce the 
efficacy of these treatments. The critical finding, in this study, that hMSCs may increase 
mineralized osteophyte volume must also be taken into strong consideration in assessing 
these hMSC treatments. This potential side effect presents concern as it relates not only 
to the efficacy of these treatments but for patient safety and therefore is an issue that must 
be monitored closely. This study has high clinical relevance and with clinical practice 
running well ahead of current scientific evidence, it is imperative that these findings be 
considered not only in pre-clinical work but in current and future clinical trials.   
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CONCLUSION 
 
In conclusion, the results of this study demonstrate the efficacy of encapsulated 
hMSCs as a promising disease modifying drug for OA in a pre-clinical rat model. Studies 
are ongoing to further validate treatment effectiveness of the encapsulated hMSCs. 
Additional surgeries for both the 3-week and 6-week surgeries are currently ongoing to 
fully power each of these studies. Completion of full power studies will allow for the 
trends noted throughout to be verified and will allow for more significant takeaways to be 
made from each of the respective studies. A priori power analysis with an: effect size = 
0.47, alpha = 0.05 and power = 0.95, yielded a total sample size of 48 to fully power each 
respective study.  
Controls are also being added to each of the respective studies. For both studies, 
unencapsulated scaffold free hMSCs will be added as a control to further qualify the 
effects of the paracrine signaling properties of encapsulated hMSCs; as the 
unencapsulated cells will be able to readily integrate into the native tissue. The current 
approach used in the study assumes that the mechanical barrier provided by encapsulation 
prevents direct integration of the hMSCs into the native tissue and therefore assumes 
these cells are acting through their paracrine mechanisms alone. The mineralized 
osteophyte data is a critical finding in this study but still requires proper controls for 
substantiated conclusions to be made from the results. It is important to note that the 
increased mineralized osteophyte volumes were detected for encapsulated hMSCs. 
Inclusion of unencapsulated hMSCs will allow for further delineations to be made 
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pertaining to the effects of the hMSCs alone, which will assess direct cellular integration,  
and encapsulated hMSCs, assessing cellular paracrine signaling properties, in yielding 
increased mineralized osteophyte volumes. An Empty Capsule group will also be added 
to the 6-week study. This is a critical control, as previous studies have demonstrated the 
high osteogenic potential of alginate scaffolds (Li, Chen et al. 2007).  
Histological assessments will also be run on all collected tibia samples and will be 
scored according to the established scoring metric system, the Mankin system. 
Histological assessment will permit further evaluation of the articular cartilage structure, 
state of the native chondrocytes and the identification of the presence of immune cells. 
These assessments will be compared back to the microCT quantitative analysis, providing 
more insight into the efficacy of the study treatment. The paracrine signaling properties 
of the encapsulated hMSCs may also be further analyzed in vitro by exposing the 
encapsulated cells to common OA inflammatory cytokines and analyzing the resulting 
secretome of the hMSCs.  
Sodium alginate scaffolds have shown enhanced retention profiles in the knee 
space, compared to scaffold free cellular injections, but further analysis will be crucial to 
further validate the effectiveness of these scaffolds in enhancing hMSC viability. The 
cellular viability of encapsulated hMSCs, in comparison to hMSCs alone, will be 
assessed using luciferase expressing hMSCs. These findings will further validate the 
efficacy of sodium alginate capsules as scaffolds that enhance both cellular retention and 
viability in the knee space following intra-articular injection.  
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Retention profiles will also be rerun to address some issues that were faced with 
the initial experimental run. The study needs to be fully powered and additional controls 
need to be added. A priori power analysis with an: effect size = 0.80, alpha = 0.05 and 
power = 0.95, yielded a total sample size of 10 to fully power the study. In the next 
iteration of the retention experiment a control for the NIR bead, used to label the capsule, 
clearance will be included. Additionally, histological preparations for animals used in the 
retention and cellular viability studies will be analyzed in order to identify any potential 
remnants of the sodium alginate capsules or hMSCs, which may have potentially 
integrated in the native tissues following capsule breakdown.  
The current results, taken together, suggest that encapsulation with sodium 
alginate provides an effective scaffold which may enhance hMSC retention in the knee 
space. This enhanced cellular retention appears to mediate a longer acting paracrine 
signaling effect of the hMSCs on the joint space. While this may be beneficial for 
cartilage it may also account for the increased mineralized osteophyte volume and 
subchondral bone changes. These promising findings will continue to be further validated 
and may potentially be translated into larger animal models in future studies. 
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